Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Change in Account Payables (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Change in Account Payables for 4 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 92.26% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.5 million, a 136.34% increase, with the full-year FY2024 number at -$4.6 million, down 68.44% from a year prior.
  • Change in Account Payables was $3.3 million for Q3 2025 at Centessa Pharmaceuticals, up from $177000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $3.3 million in Q3 2025 to a low of -$4.2 million in Q1 2024.
  • A 4-year average of $27066.7 and a median of $143000.0 in 2024 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: crashed 185.51% in 2023, then soared 1955.42% in 2024.
  • Centessa Pharmaceuticals' Change in Account Payables stood at $2.6 million in 2022, then crashed by 77.43% to $586000.0 in 2023, then tumbled by 75.6% to $143000.0 in 2024, then surged by 2193.71% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Change in Account Payables are $3.3 million (Q3 2025), $177000.0 (Q2 2025), and -$2.1 million (Q1 2025).